Ann: FDA Accepts Mesoblast's BLA Resubmission for Remestemcel-L, page-707

"But surely on top of your economic and financial acumen, you couldn't be such an eminent scientist so as to be able to be so categorical when assessing the chances of Mesoblast with the FDA."

Concur wholeheartedly.

I could never be categorical about a subject in which I'm not qualified, such as assessing MSB's chances with the FDA [*].

Which is why I don't try.

But where I like to think I am in a position to be categorical is in the area in which I like to think I am sufficiently qualified and experienced, namely in assessing the capital adequacy of a company.

Which is why I have always confined my assessment to that aspect of the company, i.e., the extent to which it is approaching the point of self-sustaining commercialisation.


[*] In fact, I put it to you that very few people in the world are able to be categorical about it (evidently not even the company's managers themselves, based on history)

.